✨
AI Summary
- BlueSphere Bio CEO Dr. David Apelian explains the challenges of treating solid tumor cancers.
- He outlines what the CGT sector needs to address for short-term success.
- The focus is on advancing therapies for difficult-to-treat cancers.
Guests on This Episode
DA
David Apelian
1 podcast appearance